This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Alert me on articles by topic

The Promise and the Problem

Arch Neurol. 2005;62:1506-1507.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Immunization therapy for Alzheimer disease (AD) entered the realm of possibility with the startling publication in 1999 by Schenk et al¹ of the successful immunization of transgenic mice carrying a human mutant gene for the amyloid precursor protein, causal of early onset AD,^1-2 that resulted in a striking reduction in brain amyloid burden with reduced gliosis and dystrophic neurites in immunized -amyloid_(1-42) (A_[1-42])–transgenic mice. As a result of the highly positive reduction of amyloid burden in A_(1-42)-immunized transgenic mice with improved behavior and memory,^3-4 a phase II double-blind, placebo-controlled, multicenter study was conducted to evaluate safety, tolerability, and pilot efficacy of AN1792 (A_[1-42]) administered with AS21 adjuvant in 372 patients with mild to moderate AD. Unfortunately, this study had to be stopped owing to the development of meningoencephalitis associated with AN1792 immunization in 18 of 300 immunized patients. By the time the study was discontinued, 24 patients . . . [Full Text of this Article]

AUTHOR INFORMATION

Roger N. Rosenberg, MD, Editor

RELATED ARTICLE

Risk Factors Associated With -Amyloid_(1-42) Immunotherapy in Preimmunization Gene Expression Patterns of Blood Cells
Margot O’Toole, Derek B. Janszen, Donna K. Slonim, Padmalatha S. Reddy, Debra K. Ellis, Holly M. Legault, Andrew A. Hill, Maryann Z. Whitley, William M. Mounts, Krystyna Zuberek, Frederick W. Immermann, Ronald S. Black, and Andrew J. Dorner
Arch Neurol. 2005;62(10):1531-1536.
ABSTRACT | FULL TEXT